Sarju Ganatra to Adverse Drug Reaction Reporting Systems
This is a "connection" page, showing publications Sarju Ganatra has written about Adverse Drug Reaction Reporting Systems.
Connection Strength
0.472
-
Yukselen Z, Raju AKV, Kumar PA, Ujjawal A, Dasari M, Parajuli S, Nakhla M, Bansal K, Ganatra S, Dani SS. A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten. Am J Cardiovasc Drugs. 2024 Nov; 24(6):791-799.
Score: 0.228
-
Batra A, Patel B, Addison D, Baldassarre LA, Desai N, Weintraub N, Deswal A, Hussain Z, Brown SA, Ganatra S, Agarwala V, Parikh PM, Fradley M, Ghosh A, Guha A. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021 12; 8(2).
Score: 0.189
-
Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials. Curr Probl Cardiol. 2024 Sep; 49(9):102664.
Score: 0.056